臺灣人文及社會科學引文索引資料庫系統

:::

詳目顯示

回上一頁
第 1 筆 / 總合 1 筆   第一頁 上一頁 下一頁 最後一頁
/1頁
題名：人類乳突病毒疫苗接種政策：公共衛生倫理觀點
書刊名：臺灣公共衛生雜誌
作者：詹明錦／邱勝康／吳建昌／方啟泰 引用關係
作者(外文)：Chan, Min-chin／Chiu, Shen-kang／Wu, Kevin Chien-chang／Fang, Chi-tai
出版日期：2013
卷期：32:4
頁次：頁309-319
主題關鍵詞：人類乳突病毒；疫苗；子宮頸癌；公共衛生倫理；Human papillomavirus；Vaccine；Cervical cancer；Public health ethics
原始連結：連回原系統網址new window
相關次數：
  • 被引用次數被引用次數:期刊(3) 博士論文(0) 專書(0) 專書論文(0)
  • 排除自我引用排除自我引用:3
  • 共同引用共同引用:0
  • 點閱點閱:164
人類乳突病毒(Human papillomavirus, HPV)是子宮頸癌的主要致病因子。目前已有兩種HPV疫苗，分別為四價(HPV-6, 11, 16及18)及二價(HPV-16, 18)，核准於26歲以下的青少女使用。由於定價昂貴，且長期保護力及疫苗安全性有待觀察，對HPV 疫苗接種政策出現若干不同意見。本文回顧相關文獻，並從美國Centers for Diseases Control and Prevention與Public Health Leadership Society共同制定的歷史性文獻Principles of the Ethical Practice of Public Health所揭櫫的公共衛生倫理(Public health ethics)原則來剖析「是否應強制全面接種HPV疫苗」及「是否應公費補助接種HPV疫苗」兩個議題。我們認為，在目前有限之資料下，是否強制施打，仍有商榷餘地，將來更需要進行公開透明之政策討論，取得公眾之信任，以決定HPV疫苗之強制施打是否能夠通過比例原則之考量。是否公費補助則必須考量成本效益，在最佳條件之假設下，成本效益分析顯示HPV疫苗在台灣具成本效益，因此，以公費補助低收入戶少女接種HPV疫苗，應是目前適當的做法。
Human papillomavirus (HPV) is a major factor in the etiology of cervical cancer. Two HPV vaccines, HPV4 (against HPV types 6, 11, 16, and 18) and HPV2 (against HPV 16 and 18), have been approved for adolescent girls younger than age 26. Due to concerns about the price, duration of protection, and vaccine safety, opinions differ on HPV vaccination policy. We reviewed the literature, and considered two issues from the public health ethics perspective highlighted in “Principles of the Ethical Practice of Public Health” co-issued by the United States Centers for Diseases Control and Prevention and the Public Health Leadership Society: (1) whether or not HPV vaccination should be mandatory, and (2) whether HPV vaccination should be paid for by the government. Given the limited current information, it is still debatable whether to adopt an obligatory HPV vaccination program. In the future, it will be necessary for policy makers to engage the public in open and transparent deliberation and earn the public’s trust in seeing obligatory HPV vaccination as compatible with the principle of proportionality. In the best case scenario, analysis shows that it is cost-effective for people to voluntarily receive HPV vaccination. Currently, it is appropriate for the government to provide financial support to girls from low-income families.
期刊論文
1.WHO(2009)。Human papillomavirus vaccines. WHO position paper。Wkly Epidemiol Rec，84，118-131。  new window
2.Chen, H. C.、You, S. L.、Hsieh, C. Y.(2011)。Prevalence of genotype-specific human papillomavirus infection and cervical neoplasia in Taiwan: a communitybased survey of 10,602 women。Int J Cancer，128，1192-1203。  new window
3.Dunne, Eileen F.、Unger, Elizabeth R.、Sternberg, Maya、McQuillan, Geraldine、Swan, David C.、Patel, Sonya S.、Markowitz, Lauri E.(2007)。Prevalence of HPV infection among females in the United States。JAMA，297(8)，813-819。  new window
4.Ho, G. Y.、Bierman, R.、Beardsley, L.、Chang, C. J.、Bur, R. D.(1998)。Natural history of cervicovaginal papillomavirus infection in young women。N Engl J Med，338，423-428。  new window
5.Arbyn, M.、Anttila, A.、Jordan, J.、Ronco, G.、Schenck, U.、Segnan, N.、Wiener, H.、Herbert, A.、Von Karsa, L.(2010)。European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition - Summary Document。Annals of Oncology，21(3)，448-458。  new window
6.Schiffman, M.、Solomon, D.(2003)。Findings to date from the ASCUS-LSIL Triage Study (ALTS)。Archives of Pathology & Laboratory Medicine，127(8)，946-949。  new window
7.Lehtinen, M.、Paavonen, J.、Wheeler, C. M.(2012)。Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial。Lancet Oncol，13，89-99。  new window
8.FUTURE I/II Study Group、Dillner, J.、Kjaer, S. K.(2010)。Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial。BMJ，341，3493。  new window
9.Muñoz, N.、Kjaer, S. K.、Sigurdsson, K.(2010)。Impact of human papillomavirus (HPV)- 6/11/16/18 vaccine on all HPV-associated genital diseases in young women。J Natl Cancer Inst，102，325-339。  new window
10.GlaxoSmithKline Vaccine HPV-007 Study Group、Romanowski, B.、de Borba, P. C.(2009)。Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years。Lancet，374，1975-1985。  new window
11.Slade, B. A.、Leidel, L.、Vellozzi, C.(2009)。Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine。JAMA，302，750-757。  new window
12.CDC(2008)。Syncope after vaccination: United States, January 2005-July 2007。MMWR Morb Mortal Wkly Rep，57，457-460。  new window
13.Markowitz, Lauri E.、Dunne, Eileen F.、Saraiya, Mona、Lawson, Herschel W.、Chesson, Harrell、Unger, Elizabeth R.(2007)。Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)。MMWR Recomm Rep，56(RR-2)，1-24。  new window
14.USCDC(2010)。FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)。MMWR Morb Mortal Wkly Rep，59(20)，626-629。  new window
15.CDC(2011)。Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011。MMWR Morb Mortal Wkly Rep，60，1705-1708。  new window
16.Colgrove, J.(2006)。The ethics and politics of compulsory HPV vaccination。N Engl J Med，355，2389-2391。  new window
17.Charo, R. A.(2007)。Politics, parents, and prophylaxis-mandating HPV vaccination in the United States。N Engl J Med，356，1905-1908。  new window
18.Gostin, L. O.、DeAngelis, C. D.(2007)。Mandatory HPV vaccination: public health vs private wealth。JAMA，297，1921-1923。  new window
19.Schwartz, J. L.(2010)。HPV vaccination’s second act: promotion, competition, and compulsion。Am J Public Health，100，1841-1844。  new window
20.Vamos, C. A.、McDermott, R. J.、Daley, E. M.(2008)。The HPV vaccine: framing the arguments for and against mandatory vaccination of all middle school girls。J Sch Health，78，302-309。  new window
21.Colgrove, J.、Abiola, S.、Mello, M. M.(2010)。HPV vaccination mandates-lawmaking amid political and scientific controversy。N Engl J Med，363，785-791。  new window
22.Opel, D. J.、Diekema, D. S.、Marcuse, E. K.(2008)。A critique of criteria for evaluating vaccines for inclusion in mandatory school immunization programs。Pediatrics，122，504-510。  new window
23.Gostin, L. O.(2011)。Mandatory HPV vaccination and political debate。JAMA，306，1699-1700。  new window
24.Gerhardus, A.、Razum, O.(2010)。A long story made too short: surrogate variables and the communication of HPV vaccine trial results。J Epidemiol Community Health，64，377-378。  new window
25.Tomljenovic, L.、Shaw, C. A.(2013)。Human papillovirus (HPV) vaccine policy and evidence-based medicine: are they at odds?。Ann Med，45，182-193。  new window
26.Goldie, S. J.、Kohli, M.、Grima, D.(2004)。Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine。J Natl Cancer Inst，8，604-615。  new window
27.Elbasha, E. H.、Dasbach, E. J.、Insinga, R. P.(2007)。Model for assessing human papillomavirus vaccination strategies。Emerg Infect Dis，13，28-41。  new window
28.Dasbach, E. J.、Insinga, R. P.、Yang, Y. C.、Pwu, R. F.、Lac, C.、Elbasha, E. H.(2008)。The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan。Asian Pac J Cancer Prev，9，459-466。  new window
29.Liu, P. H.、Hu, F. C.、Lee, P. I.、Chow, S. N.、Huang, C. W.、Wang, J. D.(2010)。Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan。BMC Health Serv Res，10，11。  new window
30.Agosti, J. M.、Goldie, S. J.(2007)。Introducing HPV vaccine in developing countries-key challenges and issues。N Engl J Med，356，1908-1910。  new window
31.Bogaards, J. A.、Coupé, V. M.、Meijer, C. J.、Berkhof, J.(2011)。The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands。Vaccine，29，8929-8936。  new window
32.Chen, H. C.、Schiffman, M.、Lin, C. Y.(2011)。Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer。J Natl Cancer Inst，103，1387-1396。  new window
33.Childress, James F.、Faden, Ruth R.、Gaare, Ruth D.、Gostin, Lawrence O.、Kahn, Jeffrey、Bonnie, Richard J.、Kass, Nancy E.、Mastroianni, Anna C.、Moreno, Jonathan D.、Nieburg, Phillip(2002)。Public Health Ethics: Mapping the Terrain。Journal of Law, Medicine and Ethics，30(2)，170-178。  new window
圖書
1.WHO(2007)。Human Papillomavirus and HPV Vaccines: Technical Information for Policy-Makers and Health Professionals。Geneva：WHO。  new window
2.Beauchamp, Tom L.、Childress, James F.(2009)。Principles of Biomedical Ethics。Oxford University Press。  new window
其他
1.美商默沙東藥廠股份有限公司台灣分公司。嘉喜®四價人類乳突病毒（第6、11、16、18型）基因重組疫苗仿單，http://www.hpvcare.com.tw/HPV_instruction/GARDASIL%20TWPC.pdf， 2012/06/10。  延伸查詢new window
2.荷商葛蘭素史克藥廠股份有限公司台灣分公司。保蓓TM人類乳突病毒第16／18型疫苗（基因重組；使用AS04佐劑）仿單，http://www.gsk.tw/PDF/vaccines/Cervarix.pdf， 2012/06/10。  延伸查詢new window
3.Centers for Diseases Control and Prevention。Vaccine safety: summary of HPV adverse reports published in JAMA，http://www.cdc.gov/vaccinesafety/Vaccines/HPV/jama.html， 2012/06/12。  new window
4.National Conference of State Legislatures(201206)。HPV vaccine: state legislations and statutes，http://www.ncsl.org/issuesresearch/health/hpv-vaccine-state-legislation-andstatutes.aspx， 2012/06/12。  new window
5.王鴻國。北縣85年次女生子宮頸癌疫苗免費打，http://npo9867.npo.nat.gov.tw/#_Toc203451551， 2010/03/22。  延伸查詢new window
6.行政院衛生署國民健康局(20110411)。4月11日開始補助全國低收入戶及山地離島國中一至三年級女生接種人類乳突病毒疫苗，http://www.bhp.doh.gov.tw/BHPnet/Portal/AchieventShow.aspx?No=201105160002， 2012/06/13。  延伸查詢new window
7.台灣女人連線。政府預算應做合理分配--呼籲各地方政府暫緩施打HPV疫苗，http://twl.ngo.org.tw/health_word.asp?artid=00088&artcatid=00002&artcatnm=相關政策&nouse=2210， 2012/06/13。  延伸查詢new window
8.CDC。Public health ethics，http://www.cdc.gov/od/science/integrity/phethics/， 2012/06/17。  new window
9.Thomas, J. C.。Module 1: distinguishing public health ethics from medical ethics，http://oce.sph.unc.edu/phethics/module1/presentation.htm， 2012/06/17。  new window
10.Public Health Leadership Society。Principles of the ethical practice of public health，http://www.apha.org/NR/rdonlyres/1CED3CEA-287E-4185-9CBD-BD405FC60856/0/ethicsbrochure.pdf， 2012/06/17。  new window
11.WHO。Cost-effectiveness thresholds，http://www.who.int/choice/costs/CER_thresholds/en/print.html， 2012/06/18。  new window
12.行政院主計總處(2011)。國民所得與平均每人國民所得，http://www.dgbas.gov.tw/public/data/dgbas03/bs4/NiYB/c1/1-3.doc， 2012/07/09。  延伸查詢new window
 
 
 
 
第一頁 上一頁 下一頁 最後一頁 top
QR Code
QRCODE

臺灣人文及社會科學引文索引資料庫

目前上線人數：397（臺灣：396，外國：1） ／ 本年度總使用人次：1695817 ／ 訪客人次（自102年09月）：67504929
國家圖書館著作權聲明 Copyright © 2013 All rights reserved.
本館地址: 100201臺北市中山南路20號． 本館地圖及交通資訊．
總機：(02)23619132．最佳瀏覽解析度為1024x768以上